Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study

doi:10.3748/wjg.v13.i2.294

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1759)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

198

HTML

1258

Figures (1-1)

174

Tables (1-3)

129

Sum=1759

Jan 14, 2007 (publication date) through Apr 22, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jan 14, 2007; 13(2): 294-298
Published online Jan 14, 2007. doi: 10.3748/wjg.v13.i2.294

Table 1 Characteristics of patients and controls (mean ± SD)

Characteristic	Patient group(n = 38)	Control group(n = 40)	P
Age (yr)	41.1 ± 10.3 ^a	34.2 ± 14.2	0.017
Male/Female	30/8 ^b	20/20	0.010
BMI (kg/m²)	24.8 ± 4.7	24.3 ± 4.9	0.691
Smoking n (%)	25 (65.8) ^b	3 (7.5)	< 0.001
Alcohol n (%)	6 (15.8)	1 (2.5)	0.054
History of iv drug use n (%)	9 (23.7) ^b	0 (0)	0.001

^aP < 0.05,

^bP < 0.01 vs control group.

Table 2 Characteristics of hepatitis C patients according to vaccine response (mean ± SD)

Characteristics	Non-responder(n = 10)	Responder(n =28)	P
Age (yr)	41.5 ± 11.3	41.0 ± 10.2	0.897
Male/Female	8/2	22/6	1.000
BMI (kg/m²)	26.6 ± 6.0	24.2 ± 4.1	0.192
Smoking n (%)	9 (90.0)	16 (57.1)	0.118
Alcohol n (%)	2 (20.0)	4 (14.3)	0.644
Hx of iv drug use n (%)	2 (20.0)	7 (25.0)	1.000
ALT (IU/L)	177.1 ± 293.9	78.3 ± 165.3	0.199
Liver disease
HAI grade (0-18)¹	5.4 ± 2.1	5.6 ± 1.9	0.773
HAI stage (0-6)¹	2.3 ± 1.1	2.6 ± 1.6	0.669
HCV genotype n (%)	8	26
1a	6 (75.0)	14 (53.8)	0.422
Other than 1a	2 (25.0)	12 (46.2)

¹According to Knodell’s histological activity index (HAI) as modified by Ishak et al[25]. Non-responder (anti-HBs < 10 IU/L); Responder (anti-HBs > 10 IU/L). Hx:history. .

Table 3 Characteristics of hepatitis C patients according to vaccine response

Characteristic	Non-responder(n = 10)	Low-responder(n = 8)	High-responder(n = 20)	P
Age (yr)	41.5 ± 11.3	46.1 ± 9.0	39.0 ± 10.1	0.394
Male/Female	8/2	5/3	17/3	0.417
BMI (kg/m²)	26.6 ± 6.0	24.9 ± 3.0	23.8 ± 4.6	0.903
Smoking n (%)	9 (90.0)	4 (50.0)	12 (60.0)	0.150
Alcohol n (%)	2 (20.0)	0 (0)	4 (20.0)	0.387
Hx of iv drug use n (%)	2 (20.0)	2 (25.0)	5 (25.0)	0.950
ALT (IU/L)	177.1 ± 293.9	149.8 ± 304.6	49.8 ± 40.3	0.711
Liver disease
HAI grade (0-18)	5.4 ± 2.1	5.4 ± 2.8	5.7 ± 1.3	0.607
HAI stage (0-6)	2.3 ± 1.1	2.4 ± 1.8	2.7 ± 1.5	0.986
HCV genotype n (%)	8	8	18
1a	6 (75.0)^a	7 (87.5)^a	7 (38.9)^a	0.038
Other than 1a	2 (25.0)	1 (12.5)	11 (61.1)

Non-responder (anti-HBs < 10 IU/L); Low-responder (10 IU/L < anti-HBs < 100 IU/L); High-responder (anti-HBs > 100 IU/L).

^aP < 0.05 comparison between three groups.

Citation: Daryani NE, Nassiri-Toosi M, Rashidi A, Khodarahmi I. Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study. World J Gastroenterol 2007; 13(2): 294-298
URL: https://www.wjgnet.com/1007-9327/full/v13/i2/294.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i2.294